{"protocolSection": {"identificationModule": {"nctId": "NCT00681629", "orgStudyIdInfo": {"id": "D1443L00048"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Schizophrenic Patients in Integrated Care", "officialTitle": "CARE II - Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-country, Multi-centre Phase IV Study", "acronym": "CARE II"}, "statusModule": {"statusVerifiedDate": "2012-06", "overallStatus": "TERMINATED", "whyStopped": "Difficulty finding eligible sites/patients; current situation in health policy cause negative effect on existing/planned contracts for integrated care program", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-07"}, "primaryCompletionDateStruct": {"date": "2008-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-05-20", "studyFirstSubmitQcDate": "2008-05-20", "studyFirstPostDateStruct": {"date": "2008-05-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-04-07", "resultsFirstSubmitQcDate": "2012-06-22", "resultsFirstPostDateStruct": {"date": "2012-07-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-06-22", "lastUpdatePostDateStruct": {"date": "2012-07-30", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a period of 18 month"}, "conditionsModule": {"conditions": ["Schizophrenia", "Schizoaffective Disorder", "Schizophreniform Disorder"], "keywords": ["Schizophrenia", "Integrated Care", "Quetiapine"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 7, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Quetiapine XR Alone", "type": "EXPERIMENTAL", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion", "interventionNames": ["Drug: Quetiapine XR"]}, {"label": "Quetiapine XR With Integrated Care Program (ICP)", "type": "EXPERIMENTAL", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion", "interventionNames": ["Drug: Quetiapine XR", "Other: Integrated Care Program (ICP)"]}], "interventions": [{"type": "DRUG", "name": "Quetiapine XR", "description": "400-800 mg, oral, bid", "armGroupLabels": ["Quetiapine XR Alone", "Quetiapine XR With Integrated Care Program (ICP)"], "otherNames": ["Seroquel Prolong"]}, {"type": "OTHER", "name": "Integrated Care Program (ICP)", "description": "Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.", "armGroupLabels": ["Quetiapine XR With Integrated Care Program (ICP)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Subjective Well-being in Patients Treated for Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder or Psychotic Disorder Not Otherwise Specified Using the SWN-K (Subjective Well-being Under Neuroleptics) Scale", "description": "The SWN-K is comprised of 20 questions, each of which is rated using a 6 point scale ranging from 1 (not at all) to 6 (very much). Possible scores range from 20-120, with higher scores implying higher subjective well-being.", "timeFrame": "4 months"}], "secondaryOutcomes": [{"measure": "Subjective Well-being Using the SWN-K (Subjective Well-being Under Neuroleptics Scale) Total Score", "description": "The SWN-K is comprised of 20 questions, each of which is rated using a 6 point scale ranging from 1 (not at all) to 6 (very much). Possible scores range from 20-120, with higher scores implying higher subjective well-being.", "timeFrame": "4 month"}, {"measure": "Symptomatic Outcome Using CGI-S (Clinical Global Impression-Schizophrenia) Scale", "description": "With the CGI-S the rate of the severity of a patient's symptoms (positive, negative, cognitive, depressive and overall) using a scale ranging from 1 (normal, not ill) to 7 (among the most severely ill) is measured - higher scores implying higher severity.", "timeFrame": "4 month"}, {"measure": "Symptomatic Outcome Using the PANSS-8 Scales(Positive and Negative Symptoms) Scale Score", "description": "The schizophrenic symptomatology will be measured by the Positive and Negative Syndrome Scale (PANSS) providing 8 items of which each is rated on a severity scale ranging from 1-7, (1= absent - 7 = extreme severe. higher scores implying higher severity.", "timeFrame": "4 month"}, {"measure": "GAF (Global Assessment of Functioning) Scale Score", "description": "The \"GAF\" is a numeric rating scale used by clinicians for assessment of the social, occupational, psychological functioning of adult patients. The scale represents a hypothetical continuum of mental health illness providing a descending scoring code from 100 until 0. Higher scores indicate better patient condition and performance.", "timeFrame": "4 month"}, {"measure": "PSP (Personal and Social Performance) Scale Score", "description": "The '(PSP\" rating scale (100 until 0) used by clinicians for assessment of 4 main domains of functioning in adult patients acc. (a) socially useful activities including work and study, (b) personal and social relationships, (c) self-care, and (d) disturbing and aggressive behavior. Higher scores indicate better patient condition and performance.", "timeFrame": "4 month"}, {"measure": "EQ-5D (European Quality of Life Questionnaire) Score", "description": "The EQ-5D questionnaire is a generic measure of health status. It defines health in terms of five dimensions:1 (Mobility); 2 (Self-care); 3 (Usual activity); 4 (Pain/Discomfort); 5 (Anxiety/Depression).\n\nThe minimum possible value is 5 (one point for each dimension) and the maximum possible values is 15 (3 points for each dimension). Each dimension has 3 levels of \"severity\"- \"no problems, \"some problems\" and \"extreme problems\". Higher scores indicate more problems.", "timeFrame": "4 month"}, {"measure": "Vocational Occupational Index \"VOC\" Score", "description": "The \"VOC\" index will assess the following 7 items: 1 fulltime gainful employment, 2 homemaker or student, 3 part-time gainful employment (20 hours per week or less), 4 retired, 5 full or part-time volunteer, 6 on medical or psychiatric leave of absence, 7 unemployed, whether or not expected to work. Results will be descriptively summarized. The VOC index will be completed at each visit. Difference from baseline of the index will be derived at each assessment", "timeFrame": "Up to 18 months (V1 Day 1, V2 Month 1, V3 Month 3, V4 Month 6, V5 Month 12, V6 Month 18)"}, {"measure": "Assess Quality of Life Levels Using the Q-LES-Q-18 (Quality of Life Enjoyment and Satisfaction) Questionnaire", "description": "Q-LES-Q-18 will allow to generate a general QoL-index which will be used for the analysis and is defined as the average of the single scores for all 18 items. Scoring will be carried out from 1-5 per item (never / rarely / sometimes / frequently / all the time). Results will be descriptively summarized.", "timeFrame": "4 month"}, {"measure": "Assess Quality of Life Levels Using the RSM Scale (Riedel-Spellmann-Musil) Scale", "description": "The '(RSM\" is a new 36-item measure validated to assess the \"QoL\" in different dimensions of schizophrenic patient treated with antipsychotics. It will be rated on a four-point Likert scale (not / rather not / rather yes / yes) by the patient and the investigator. The total score ranges from min. 0 to max. of 108. Higher scores indicate higher \"QoL\".", "timeFrame": "4 month"}, {"measure": "Assess Patient Engagement to Therapy Using the SES Scale (Service Engagement Scale)", "description": "The 'SES\" is a 14-item measure consisting of statements that assess the client specific engagement with services. It will be rated on a four-point Likert scale (not at all / rarely / sometimes / most of the time) by the investigator. The total score ranges from min. 0 to a max. of 42. Higher scores indicate lower engagement.", "timeFrame": "4 month"}, {"measure": "Assess Compliance/Medication Adherence Using the MARS Scale (Medication Adherence Rating Scale)", "description": "The 'Medication Adherence Rating Scale' (MARS) is a reliable and valid self-reporting tool for investigation of the compliance in psychiatric patients also recognizing the complexity of compliance behaviour. 10 questions on medication attitude have to be answered by 'yes' or 'no' (8 times 1= no and Yes = 0 and twice 1= no, Yes =1). Results will be descriptively summarized. Summarized results minimum 0: low medication adherence, maximum 10: high medication adherence.", "timeFrame": "4 month"}, {"measure": "Evaluate the Level of the Patients' (Subjective) Satisfaction Using the CSQ-8 Scale (Client Satisfaction Questionnaire)", "description": "The 'CSQ-8\" is a brief, self-administered method to monitor the consumer's satisfaction with services in outpatient psychotherapy, showing high internal consistency. It is identified as a core subset of the general CSQ covering 8 Likert-type items with four response choices where '1' indicates the lowest and '4' the highest degree of satisfaction.", "timeFrame": "4 month"}, {"measure": "Assess Health Economy Improvements in Terms of a Reduction in Treatment Costs and Loss of Productivity by Determination of the Total Cost by Number of Days With Hospitalization", "description": "Any hospitalisation days in inpatients units and emergency ward stays will be recorded. At each hospitalisation, the number of days will be computed and at each visit, the cumulative total number of days will be used to calculate total costs. As higher the number of hospitalisation days as higher the costs per patient.", "timeFrame": "4 month"}, {"measure": "Assess Health Economy Improvements in Terms of a Reduction in Treatment Costs and Loss of Productivity by Determination of the Total Number of Days the Patient Was Not Able to Work or go to School or Complete Routine Daily Activities", "description": "The number of lost work days, lost school days or days without completing routine daily activities will be evaluated. With any number of lost workdays or lost school days or without completing routine daily activities, the costs will increase and the productivity will decrease.", "timeFrame": "4 month"}, {"measure": "Assess Health Economy Improvements in Terms of a Reduction in Treatment Costs and Loss of Productivity by Determination of the Need for Any Additional Antipsychotic Medication", "description": "Concomitant psychotropic drugs will be coded (ATC = Drug code) to allow a comparison of the number of drugs used per ATC class and per treatment visit. The drugs used will be listed by keeping their brand name for allowing to translate them into costs.", "timeFrame": "4 month"}, {"measure": "Evaluate Safety and Tolerability by Evaluation of Weight/Waist Circumference", "description": "Measuring of weight and waist circumference in centimeter.", "timeFrame": "4 month"}, {"measure": "Evaluate Safety and Tolerability by Evaluation of Laboratory Tests", "description": "Measuring of: B-Haemoglobin (g/dl), B-Haematocrit(%), B-Erythrocyte count(pl), B-Leucocytes count (nl), B-Platelet count(nl), Complete blood count (nl), B-Leucocytes differential count (%), B-HbA1c(%), S-ALAT (U/l), S-ASAT (U/l), S-GGT (U/l), P-Glucose (fasting)(mh/dl), S-prolactin level (ng/ml), S-Pregnancy test (IU/l), Qualitative analysis of urine with Stix\u00ae,Urine pregnancy. Comparing results with standard values.", "timeFrame": "4 month"}, {"measure": "Evaluate Safety and Tolerability by Evaluation of Concomitant Medication", "description": "Listing of all concomitant medication to show the efficacy and safety.", "timeFrame": "4 month"}, {"measure": "Evaluate Safety and Tolerability by Evaluation of the Incidence of Adverse Events", "description": "Listing of all adverse event or SAE\u00b4s to show the safety and tolerability.", "timeFrame": "4 month"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with baseline SWN-K \\<=70\n* Provision of signed informed consent\n* Out-patients with schizophrenia, schizophreniform disorder or schizoaffective disorder, severe postpartum depressive disorders with psychotic symptoms and a minimum HAM-D cut off score of 20 points\n\nExclusion Criteria:\n\n* Evidence of a clinical relevant disease, eg renal or hepatic impairment, significant coronary heart disease, hepatitis B or C, AIDS\n* Patients with known cardiovascular disease or other condition predisposing to hypotension or family history of QT prolongation\n* Patients who pose an imminent risk of suicide or danger to self or others", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Martin Lambert, MD", "affiliation": "Universit\u00e4tsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Munchen", "state": "Bayern", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"facility": "Research Site", "city": "Oranienburg", "state": "Brandenburg", "country": "Germany", "geoPoint": {"lat": 52.75577, "lon": 13.24197}}, {"facility": "Research Site", "city": "Luneburg", "state": "Niedersachsen", "country": "Germany", "geoPoint": {"lat": 53.2509, "lon": 10.41409}}, {"facility": "Research Site", "city": "Oldenburg", "state": "Niedersachsen", "country": "Germany", "geoPoint": {"lat": 53.14118, "lon": 8.21467}}, {"facility": "Research Site", "city": "Chemnitz", "state": "Sachsen", "country": "Germany", "geoPoint": {"lat": 50.8357, "lon": 12.92922}}, {"facility": "Research Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Research Site", "city": "Stolberg", "country": "Germany", "geoPoint": {"lat": 50.77368, "lon": 6.22595}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Study period July 2008 to November 2008; Centre Dr. Lambert (Hamburg), Centre Dr. Dorn (Berlin)", "groups": [{"id": "FG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "FG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "It was planned to recruit 100 patient", "numSubjects": "5"}, {"groupId": "FG001", "comment": "It was planned to recruit 100 patient", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Study termination", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "BG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "7"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "18-65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Subjective Well-being in Patients Treated for Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder or Psychotic Disorder Not Otherwise Specified Using the SWN-K (Subjective Well-being Under Neuroleptics) Scale", "description": "The SWN-K is comprised of 20 questions, each of which is rated using a 6 point scale ranging from 1 (not at all) to 6 (very much). Possible scores range from 20-120, with higher scores implying higher subjective well-being.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "4 months", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Subjective Well-being Using the SWN-K (Subjective Well-being Under Neuroleptics Scale) Total Score", "description": "The SWN-K is comprised of 20 questions, each of which is rated using a 6 point scale ranging from 1 (not at all) to 6 (very much). Possible scores range from 20-120, with higher scores implying higher subjective well-being.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Symptomatic Outcome Using CGI-S (Clinical Global Impression-Schizophrenia) Scale", "description": "With the CGI-S the rate of the severity of a patient's symptoms (positive, negative, cognitive, depressive and overall) using a scale ranging from 1 (normal, not ill) to 7 (among the most severely ill) is measured - higher scores implying higher severity.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Symptomatic Outcome Using the PANSS-8 Scales(Positive and Negative Symptoms) Scale Score", "description": "The schizophrenic symptomatology will be measured by the Positive and Negative Syndrome Scale (PANSS) providing 8 items of which each is rated on a severity scale ranging from 1-7, (1= absent - 7 = extreme severe. higher scores implying higher severity.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "GAF (Global Assessment of Functioning) Scale Score", "description": "The \"GAF\" is a numeric rating scale used by clinicians for assessment of the social, occupational, psychological functioning of adult patients. The scale represents a hypothetical continuum of mental health illness providing a descending scoring code from 100 until 0. Higher scores indicate better patient condition and performance.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "PSP (Personal and Social Performance) Scale Score", "description": "The '(PSP\" rating scale (100 until 0) used by clinicians for assessment of 4 main domains of functioning in adult patients acc. (a) socially useful activities including work and study, (b) personal and social relationships, (c) self-care, and (d) disturbing and aggressive behavior. Higher scores indicate better patient condition and performance.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "EQ-5D (European Quality of Life Questionnaire) Score", "description": "The EQ-5D questionnaire is a generic measure of health status. It defines health in terms of five dimensions:1 (Mobility); 2 (Self-care); 3 (Usual activity); 4 (Pain/Discomfort); 5 (Anxiety/Depression).\n\nThe minimum possible value is 5 (one point for each dimension) and the maximum possible values is 15 (3 points for each dimension). Each dimension has 3 levels of \"severity\"- \"no problems, \"some problems\" and \"extreme problems\". Higher scores indicate more problems.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Vocational Occupational Index \"VOC\" Score", "description": "The \"VOC\" index will assess the following 7 items: 1 fulltime gainful employment, 2 homemaker or student, 3 part-time gainful employment (20 hours per week or less), 4 retired, 5 full or part-time volunteer, 6 on medical or psychiatric leave of absence, 7 unemployed, whether or not expected to work. Results will be descriptively summarized. The VOC index will be completed at each visit. Difference from baseline of the index will be derived at each assessment", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Up to 18 months (V1 Day 1, V2 Month 1, V3 Month 3, V4 Month 6, V5 Month 12, V6 Month 18)", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Assess Quality of Life Levels Using the Q-LES-Q-18 (Quality of Life Enjoyment and Satisfaction) Questionnaire", "description": "Q-LES-Q-18 will allow to generate a general QoL-index which will be used for the analysis and is defined as the average of the single scores for all 18 items. Scoring will be carried out from 1-5 per item (never / rarely / sometimes / frequently / all the time). Results will be descriptively summarized.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Assess Quality of Life Levels Using the RSM Scale (Riedel-Spellmann-Musil) Scale", "description": "The '(RSM\" is a new 36-item measure validated to assess the \"QoL\" in different dimensions of schizophrenic patient treated with antipsychotics. It will be rated on a four-point Likert scale (not / rather not / rather yes / yes) by the patient and the investigator. The total score ranges from min. 0 to max. of 108. Higher scores indicate higher \"QoL\".", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Assess Patient Engagement to Therapy Using the SES Scale (Service Engagement Scale)", "description": "The 'SES\" is a 14-item measure consisting of statements that assess the client specific engagement with services. It will be rated on a four-point Likert scale (not at all / rarely / sometimes / most of the time) by the investigator. The total score ranges from min. 0 to a max. of 42. Higher scores indicate lower engagement.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Assess Compliance/Medication Adherence Using the MARS Scale (Medication Adherence Rating Scale)", "description": "The 'Medication Adherence Rating Scale' (MARS) is a reliable and valid self-reporting tool for investigation of the compliance in psychiatric patients also recognizing the complexity of compliance behaviour. 10 questions on medication attitude have to be answered by 'yes' or 'no' (8 times 1= no and Yes = 0 and twice 1= no, Yes =1). Results will be descriptively summarized. Summarized results minimum 0: low medication adherence, maximum 10: high medication adherence.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Evaluate the Level of the Patients' (Subjective) Satisfaction Using the CSQ-8 Scale (Client Satisfaction Questionnaire)", "description": "The 'CSQ-8\" is a brief, self-administered method to monitor the consumer's satisfaction with services in outpatient psychotherapy, showing high internal consistency. It is identified as a core subset of the general CSQ covering 8 Likert-type items with four response choices where '1' indicates the lowest and '4' the highest degree of satisfaction.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Assess Health Economy Improvements in Terms of a Reduction in Treatment Costs and Loss of Productivity by Determination of the Total Cost by Number of Days With Hospitalization", "description": "Any hospitalisation days in inpatients units and emergency ward stays will be recorded. At each hospitalisation, the number of days will be computed and at each visit, the cumulative total number of days will be used to calculate total costs. As higher the number of hospitalisation days as higher the costs per patient.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Assess Health Economy Improvements in Terms of a Reduction in Treatment Costs and Loss of Productivity by Determination of the Total Number of Days the Patient Was Not Able to Work or go to School or Complete Routine Daily Activities", "description": "The number of lost work days, lost school days or days without completing routine daily activities will be evaluated. With any number of lost workdays or lost school days or without completing routine daily activities, the costs will increase and the productivity will decrease.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Assess Health Economy Improvements in Terms of a Reduction in Treatment Costs and Loss of Productivity by Determination of the Need for Any Additional Antipsychotic Medication", "description": "Concomitant psychotropic drugs will be coded (ATC = Drug code) to allow a comparison of the number of drugs used per ATC class and per treatment visit. The drugs used will be listed by keeping their brand name for allowing to translate them into costs.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Drugs", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Evaluate Safety and Tolerability by Evaluation of Weight/Waist Circumference", "description": "Measuring of weight and waist circumference in centimeter.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "centimeters", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Evaluate Safety and Tolerability by Evaluation of Laboratory Tests", "description": "Measuring of: B-Haemoglobin (g/dl), B-Haematocrit(%), B-Erythrocyte count(pl), B-Leucocytes count (nl), B-Platelet count(nl), Complete blood count (nl), B-Leucocytes differential count (%), B-HbA1c(%), S-ALAT (U/l), S-ASAT (U/l), S-GGT (U/l), P-Glucose (fasting)(mh/dl), S-prolactin level (ng/ml), S-Pregnancy test (IU/l), Qualitative analysis of urine with Stix\u00ae,Urine pregnancy. Comparing results with standard values.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "depending on the Lab test (see above)", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Evaluate Safety and Tolerability by Evaluation of Concomitant Medication", "description": "Listing of all concomitant medication to show the efficacy and safety.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Name of concomitant medication", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Evaluate Safety and Tolerability by Evaluation of the Incidence of Adverse Events", "description": "Listing of all adverse event or SAE\u00b4s to show the safety and tolerability.", "populationDescription": "No data were reported as no participants completed the study", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "number of events", "timeFrame": "4 month", "groups": [{"id": "OG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance."}, {"id": "OG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Quetiapine XR With Integrated Care Program (ICP)", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion.\n\nIntegrated Care Program (ICP) is a legally based integrated care program covered by a contract according to \u00a7\u00a7 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.", "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 2, "otherNumAtRisk": 5}, {"id": "EG001", "title": "Quetiapine XR Alone", "description": "Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator\u00b4s discretion", "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 1, "otherNumAtRisk": 2}], "otherEvents": [{"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 2}]}, {"term": "Dry Mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Weight Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 2}]}, {"term": "Neck Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 2}]}, {"term": "Abnormal Dreams", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Suicidal Ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 2}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The study was stopped due to poor enrollment and no data analysis was performed."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Site has to inform sponsor about a publication at least 60 day in advance and 10 days before submission of an abstract or presentation. Change requests by the sponsor are recognized unless the scientific character or the objectivity is on risk. If the sponsor plans a patent application the publication has to be postponed up to 120 days."}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000012559", "term": "Schizophrenia"}, {"id": "D000011618", "term": "Psychotic Disorders"}], "ancestors": [{"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}], "browseLeaves": [{"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "asFound": "Schizophreniform Disorder", "relevance": "HIGH"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069348", "term": "Quetiapine Fumarate"}], "ancestors": [{"id": "D000000928", "term": "Antidepressive Agents"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Sexual", "relevance": "HIGH"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}